All Updates

All Updates

icon
Filter
Partnerships
Exscientia and Sanofi enter strategic research partnership to develop AI-powered precision medicine pipeline
AI Drug Discovery
Jan 7, 2022
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 7, 2022

Exscientia and Sanofi enter strategic research partnership to develop AI-powered precision medicine pipeline

Partnerships

  • Exscientia, a UK-based AI drug discovery company, and leading French pharmaceutical company Sanofi have entered into a strategic research collaboration and licensing agreement to develop a pipeline of precision medicine drugs backed by AI. The partnership will allow Sanofi to expedite its drug discovery process and enhance clinical trial success rates by leveraging Exscientia’s AI-driven offering and precision medicine platform.

  • Under the terms of the partnership, Exscientia will receive an upfront cash payment of USD 100 million and up to USD 5.2 billion potentially in milestone payments and tiered royalties. The two companies will focus on discovering up to 15 novel small molecule drugs for treating cancer and immune-mediated diseases.

  • The companies have collaborated since 2016, and in 2019, the pharma giant in-licensed Exscientia’s small molecule drug candidate that targets both inflammation and immunology.

  • Exscientia is a full-stack AI drug discovery firm with discovery-to-clinical capabilities. The company uses its proprietary Centaur Chemist technology to assess disease targets specified by its clients and to prioritize potential disease targets for its own pipeline.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.